Pages that link to "Q35193237"

The following pages link to Alpha v integrin inhibitors and cancer therapy. (Q35193237):

Displaying 32 items.

• Improving outcomes in advanced malignant melanoma: update on systemic therapy (Q28244235) (← links)
• Utilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularization (Q28740612) (← links)
• Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors (Q33237917) (← links)
• Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer (Q34128953) (← links)
• Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging (Q34669572) (← links)
• Integrin alpha v beta 3-targeted imaging of lung cancer (Q34768362) (← links)
• A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma (Q35212620) (← links)
• Fistulising Crohn's disease: MMPs gone awry (Q35745017) (← links)
• 18F-FP-PEG2-β-Glu-RGD2: A Symmetric Integrin αvβ3-Targeting Radiotracer for Tumor PET Imaging (Q35784807) (← links)
• Near-infrared fluorescent divalent RGD ligand for integrin αvβ₃-targeted optical imaging (Q36177171) (← links)
• Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas (Q36230578) (← links)
• Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer (Q36603829) (← links)
• Integrin beta1 is required for the invasive behaviour but not proliferation of squamous cell carcinoma cells in vivo (Q36615726) (← links)
• First Experience with Clinical-Grade [18F]FPP(RGD)2: An Automated Multi-step Radiosynthesis for Clinical PET Studies (Q36742890) (← links)
• Gene expression profiling of the anti-glioma effect of Cilengitide (Q36824282) (← links)
• Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models (Q36884277) (← links)
• Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner (Q36935399) (← links)
• The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation (Q37027655) (← links)
• (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity (Q37218456) (← links)
• The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. (Q37604903) (← links)
• Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer (Q39218794) (← links)
• Role of the alpha v-integrin subunit in cell proliferation, apoptosis and tumor metastasis of laryngeal and hypopharyngeal squamous cell carcinomas: a clinical and in vitro investigation (Q39989827) (← links)
• (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression (Q40023168) (← links)
• A convenient clinically relevant model of human breast cancer bone metastasis. (Q40074885) (← links)
• The minimum element of a synthetic peptide required to block prostate tumor cell migration. (Q40208879) (← links)
• Ligand-mimetic anti-alphaIIb beta3 antibody PAC-1 inhibits tyrosine signaling, proliferation and lung colonization of melanoma cells (Q40334733) (← links)
• Increased expression of ADAM family members in human breast cancer and breast cancer cell lines (Q40487746) (← links)
• Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathways (Q41846875) (← links)
• Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro (Q42168743) (← links)
• Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. (Q46079015) (← links)
• [Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies] (Q80149575) (← links)
• Translocating a High-Affinity Designer TIMP-1 to the Cell Membrane for Total Renal Carcinoma Inhibition: Putting the Prion Protein to Good Use (Q92823419) (← links)